nach oben

Current Dermatology Reports

Erschienen in:

09.11.2021 | Hospital-Based Dermatology (L Guggina and C Nguyen, Section Editors)

Updates and Insights in the Diagnosis and Management of DRESS Syndrome

verfasst von: Elisa Maria Schunkert, Sherrie Jill Divito

Erschienen in: Current Dermatology Reports | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

To provide updates on recent advances in the diagnosis and management of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome.

Recent Findings

The number of identified HLA allele associations with DRESS continues to grow. There is increasing evidence indicating viral infection, reactivation, and cross-reactivity may play key roles in disease. Translational work illuminated JAK/STAT activation in recalcitrant disease. There is expanding recognition of rapid-onset DRESS resulting from specific drugs.

Summary

DRESS is a severe form of adverse drug reaction with potential for significant morbidity and mortality. Recent research advances may improve clinical care. HLA screening can now be performed to prevent disease in susceptible patients and may help identify culprit drugs in the near future. Viral testing should be performed on every patient, and if positive, patients potentially treated with antiviral therapy. JAK inhibitors may be an effective treatment option for DRESS. Early onset of disease relative to drug exposure should not exclude the diagnosis of DRESS.

Chiou CC, Yang LC, Hung SI, Chang YC, Kuo TT, Ho HC, et al. Clinicopathological features and prognosis of drug rash with eosinophilia and systemic symptoms: a study of 30 cases in Taiwan. J Eur Acad Dermatol Venereol. 2008;22(9):1044–9. https://doi.org/10.1111/j.1468-3083.2008.02585.x.CrossRefPubMed

Wolfson AR, Zhou L, Li Y, Phadke NA, Chow OA, Blumenthal KG. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome identified in the electronic health record allergy module. J Allergy Clin Immunol Pract. 2019;7(2):633–40. https://doi.org/10.1016/j.jaip.2018.08.013.CrossRefPubMed

Hiransuthikul A, Rattananupong T, Klaewsongkram J, Rerknimitr P, Pongprutthipan M, Ruxrungtham K. Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms (DIHS/DRESS): 11 years retrospective study in Thailand. Allergol Int. 2016;65(4):432–8. https://doi.org/10.1016/j.alit.2016.04.001.CrossRefPubMed

4.••

Chen CB, Wu MY, Ng CY, Lu CW, Wu J, Kao PH, et al. Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies. Cancer Manag Res. 2018;10:1259–1273. https://doi.org/10.2147/CMAR.S163391. Comprehensive review of severe delayed type cutaneous drug reactions due to targeted anticancer therapies and immunotherapies.

Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms: DRESS). Semin Cutan Med Surg. 1996;15(4):250–7. https://doi.org/10.1016/s1085-5629(96)80038-1.CrossRefPubMed

Shiohara T, Inaoka M, Kano Y. Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses. Allergol Int. 2006;55(1):1–8. https://doi.org/10.2332/allergolint.55.1.CrossRefPubMed

Kardaun SH, Sidoroff A, Valeyrie-Allanore L, Halevy S, Davidovici BB, Mockenhaupt M, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol. 2007;156(3):609–11. https://doi.org/10.1111/j.1365-2133.2006.07704.x.CrossRefPubMed

David S, Hamilton JP. Drug-induced liver injury. US Gastroenterol Hepatol Rev. 2010;6:73–80.PubMedPubMedCentral

Qadri I, Zeng X, Guo R, Koratala A. Acute interstitial nephritis and DRESS syndrome without eosinophilia associated with cefepime. BMJ Case Rep. 2017;2017. https://doi.org/10.1136/bcr-2017-221401.

10.

Augusto JF, Sayegh J, Simon A, Croue A, Chennebault JM, Cousin M, et al. A case of sulphasalazine-induced DRESS syndrome with delayed acute interstitial nephritis. Nephrol Dial Transplant. 2009;24(9):2940–2. https://doi.org/10.1093/ndt/gfp277.CrossRefPubMed

11.

Moledina DG, Perazella MA. Drug-induced acute interstitial nephritis. Clin J Am Soc Nephrol. 2017;12(12):2046–9. https://doi.org/10.2215/CJN.07630717.CrossRefPubMedPubMedCentral

12.

Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359(9308):727–32. https://doi.org/10.1016/s0140-6736(02)07873-x.CrossRefPubMed

13.•

Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358(6): 568–579. https://doi.org/10.1056/NEJMoa0706135. Double-blind, prospective, randomized study to evaluate PPV and NPV of HLA-B*57:01 in patients planning to received abacavir. Showed that HLA-B*5701 screening significantly reduced the risk of hypersensitivity reaction to abacavir.

14.

Ko TM, Tsai CY, Chen SY, Chen KS, Yu KH, Chu CS, et al. Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study. BMJ. 2015;351: h4848. https://doi.org/10.1136/bmj.h4848.CrossRefPubMedPubMedCentral

15.

Ponzo MG, Miliszewski M, Kirchhof MG, Keown PA, Dutz JP. HLA-B*58:01 genotyping to prevent cases of DRESS and SJS/TEN in East Asians treated with allopurinol-a Canadian missed opportunity [Formula: see text]. J Cutan Med Surg. 2019;23(6):595–601. https://doi.org/10.1177/1203475419867599.CrossRefPubMed

16.

Liu H, Wang Z, Bao F, Wang C, Sun L, Zhang H, et al. Evaluation of prospective HLA-B*13:01 screening to prevent dapsone hypersensitivity syndrome in patients with leprosy. JAMA Dermatol. 2019;155(6):666–72. https://doi.org/10.1001/jamadermatol.2018.5360.CrossRefPubMedPubMedCentral

17.

Divito SJ. Implementation of genetic screening to prevent severe cutaneous adverse drug reactions is crucial-rebuttal from the devil’s antagonist-reply. JAMA Dermatol. 2020;156(2):221–2. https://doi.org/10.1001/jamadermatol.2019.3335.CrossRefPubMed

18.

Ng CY, Yeh YT, Wang CW, Hung SI, Yang CH, Chang YC, et al. Impact of the HLA-B(*)58:01 allele and renal impairment on allopurinol-induced cutaneous adverse reactions. J Invest Dermatol. 2016;136(7):1373–81. https://doi.org/10.1016/j.jid.2016.02.808.CrossRefPubMed

19.

Chung WH, Chang WC, Stocker SL, Juo CG, Graham GG, Lee MH, et al. Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin. Ann Rheum Dis. 2015;74(12):2157–64. https://doi.org/10.1136/annrheumdis-2014-205577.CrossRefPubMed

20.

Sacco JC, Abouraya M, Motsinger-Reif A, Yale SH, McCarty CA, Trepanier LA. Evaluation of polymorphisms in the sulfonamide detoxification genes NAT2, CYB5A, and CYB5R3 in patients with sulfonamide hypersensitivity. Pharmacogenet Genomics. 2012;22(10):733–40. https://doi.org/10.1097/FPC.0b013e328357a735.CrossRefPubMedPubMedCentral

21.

Shear NH, Spielberg SP, Grant DM, Tang BK, Kalow W. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med. 1986;105(2):179–84. https://doi.org/10.7326/0003-4819-105-2-179.CrossRefPubMed

22.

Wolkenstein P, Charue D, Laurent P, Revuz J, Roujeau JC, Bagot M. Metabolic predisposition to cutaneous adverse drug reactions. Role in toxic epidermal necrolysis caused by sulfonamides and anticonvulsants. Arch Dermatol. 1995;131(5):544–51.

23.

Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: Part I. Clinical perspectives. J Am Acad Dermatol. 2013;68(5):693 e1–14; quiz 706–8. https://doi.org/10.1016/j.jaad.2013.01.033.

24.

Seishima M, Yamanaka S, Fujisawa T, Tohyama M, Hashimoto K. Reactivation of human herpesvirus (HHV) family members other than HHV-6 in drug-induced hypersensitivity syndrome. Br J Dermatol. 2006;155(2):344–9. https://doi.org/10.1111/j.1365-2133.2006.07332.x.CrossRefPubMed

25.

Pavlos R, White KD, Wanjalla C, Mallal SA, Phillips EJ. Severe delayed drug reactions: role of genetics and viral infections. Immunol Allergy Clin North Am. 2017;37(4):785–815. https://doi.org/10.1016/j.iac.2017.07.007.CrossRefPubMedPubMedCentral

26.••

Metterle L, Hatch L, Seminario-Vidal L. Pediatric drug reaction with eosinophilia and systemic symptoms: a systematic review of the literature. Pediatr Dermatol. 2020;37(1):124–129. https://doi.org/10.1111/pde.14044. Literature review on DRESS in the pediatric population, covering reports from 1997 to 2019 with focus on presentation and course of DRESS in children. Review of 130 cases showed that presentation, causative drugs, and mortality were largely comparable to adults.

27.••

Kardaun SH, Sekula P, Valeyrie-Allanore L, Liss Y, Chu CY, Creamer D, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013;169(5):1071–80. https://doi.org/10.1111/bjd.12501. (Systematically performed prospective observational study of 117 DRESS patients by RegiSCAR. Provides significant insight into clinical and biological characteristics, culprit drugs, and temporality of disease onset and resolution.)

28.

Kano Y, Hiraharas K, Sakuma K, Shiohara T. Several herpesviruses can reactivate in a severe drug-induced multiorgan reaction in the same sequential order as in graft-versus-host disease. Br J Dermatol. 2006;155(2):301–6. https://doi.org/10.1111/j.1365-2133.2006.07238.x.CrossRefPubMed

29.

Descamps V, Brunet-Possenti F. Drug reaction with eosinophilia and systemic symptoms or virus reactivation with eosinophilia and systemic symptoms. Pediatr Dermatol. 2016;33(5):562. https://doi.org/10.1111/pde.12931.CrossRefPubMed

30.

Herman A, Matthews M, Mairlot M, Nobile L, Fameree L, Jacquet LM, et al. Drug reaction with eosinophilia and systemic symptoms syndrome in a patient with COVID-19. J Eur Acad Dermatol Venereol. 2020;34(12):e768–800. https://doi.org/10.1111/jdv.16838.CrossRefPubMed

31.

Shiohara T, Mizukawa Y. Comment on ‘Drug reaction with eosinophilia and systemic symptoms syndrome in a patient with COVID-19’: involvement of herpesvirus reactivations and adverse drug reactions in diverse cutaneous manifestations and overall disease severity of COVID-19. J Eur Acad Dermatol Venereol. 2021;35(2):e98–100. https://doi.org/10.1111/jdv.16959.CrossRefPubMed

32.•

Almeida CA, van Miert P, O’Driscoll K, Zoet YM, Chopra A, Witt C, et al. Virus-specific T-cell clonotypes might contribute to drug hypersensitivity reactions through heterologous immunity. J Allergy Clin Immunol. 2019;144(2):608–11 e4. https://doi.org/10.1016/j.jaci.2019.05.009. Proof-of-principal in vitro study supporting T cell cross-reactivity between virus and drug as a potential pathomechanism of DRESS.

33.

Lucas A, Lucas M, Strhyn A, Keane NM, McKinnon E, Pavlos R, et al. Abacavir-reactive memory T cells are present in drug naive individuals. PLoS ONE. 2015;10(2): e0117160. https://doi.org/10.1371/journal.pone.0117160.CrossRefPubMedPubMedCentral

34.••

Kim D, Kobayashi T, Voisin B, Jo JH, Sakamoto K, Jin SP, et al. Targeted therapy guided by single-cell transcriptomic analysis in drug-induced hypersensitivity syndrome: a case report. Nat Med. 2020;26(2):236–243. https://doi.org/10.1038/s41591-019-0733-7. Excellent example of translational research and personalized medicine. Case study performing single cell analysis and supportive studies on a patient with recalcitrant DRESS demonstrating elevated Janus kinase–signal transducer and activator of transcription (JAK-STAT) pathway. The patient was subsequently successfully treated with tofacitinib.

35.

Skowron F, Bensaid B, Balme B, Depaepe L, Kanitakis J, Nosbaum A, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): clinicopathological study of 45 cases. J Eur Acad Dermatol Venereol. 2015;29(11):2199–205. https://doi.org/10.1111/jdv.13212.CrossRefPubMed

36.

Thongsri T, Chularojanamontri L, Pichler WJ. Cardiac involvement in DRESS syndrome. Asian Pac J Allergy Immunol. 2017;35(1):3–10. https://doi.org/10.12932/AP0847.CrossRefPubMed

37.

Bourgeois GP, Cafardi JA, Groysman V, Hughey LC. A review of DRESS-associated myocarditis. J Am Acad Dermatol. 2012;66(6):e229–36. https://doi.org/10.1016/j.jaad.2010.11.057.CrossRefPubMed

38.

Eshki M, Allanore L, Musette P, Milpied B, Grange A, Guillaume JC, et al. Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failure. Arch Dermatol. 2009;145(1):67–72. https://doi.org/10.1001/archderm.145.1.67.CrossRefPubMed

39.

Ozisik L, Tanriover MD, Saka E. Autoimmune limbic encephalitis and syndrome of inappropriate antidiuretic hormone secretion associated with lamotrigine-induced drug rash with eosinophilia and systemic symptoms (DRESS) syndrome. Intern Med. 2016;55(10):1393–6. https://doi.org/10.2169/internalmedicine.55.6035.CrossRefPubMed

40.••

Cabanas R, Ramirez E, Sendagorta E, Alamar R, Barranco R, Blanca-Lopez N, et al. Spanish guidelines for diagnosis, management, treatment, and prevention of DRESS syndrome. J Investig Allergol Clin Immunol. 2020;30(4):229–53. https://doi.org/10.18176/jiaci.0480. (Updated evidence-based DRESS guidelines. Provides concise summary of drugs patients could cross-react to based on their culprit drug.)

41.

Kano Y, Shiohara T. The variable clinical picture of drug-induced hypersensitivity syndrome/drug rash with eosinophilia and systemic symptoms in relation to the eliciting drug. Immunol Allergy Clin North Am. 2009;29(3):481–501. https://doi.org/10.1016/j.iac.2009.04.007.CrossRefPubMed

42.

Soria A, Bernier C, Veyrac G, Barbaud A, Puymirat E, Milpied B. Drug reaction with eosinophilia and systemic symptoms may occur within 2 weeks of drug exposure: a retrospective study. J Am Acad Dermatol. 2020;82(3):606–11. https://doi.org/10.1016/j.jaad.2019.09.036.CrossRefPubMed

43.

Milani-Nejad N, Trinidad J, Kaffenberger BH. Viral reactivation in hospitalized patients with drug reaction with eosinophilia and systemic symptoms: a retrospective study from a tertiary medical center in the United States. J Am Acad Dermatol. 2020;83(1):278–9. https://doi.org/10.1016/j.jaad.2020.03.095.CrossRefPubMed

44.

Cho YT, Yang CW, Chen YC, Chu CY. Comment on “Viral reactivation in hospitalized DRESS patients: a retrospective study from a tertiary medical center in the United States.” J Am Acad Dermatol. 2020;83(3):e209–10. https://doi.org/10.1016/j.jaad.2020.04.175.CrossRefPubMed

45.

Milani-Nejad N, Trinidad J, Kaffenberger BH. Reply to: “Comment on viral reactivation in hospitalized DRESS patients: a retrospective study from a tertiary medical center in the United States.” J Am Acad Dermatol. 2020;83(3): e211. https://doi.org/10.1016/j.jaad.2020.05.022.CrossRefPubMed

46.

Chi MH, Hui RC, Yang CH, Lin JY, Lin YT, Ho HC, et al. Histopathological analysis and clinical correlation of drug reaction with eosinophilia and systemic symptoms (DRESS). Br J Dermatol. 2014;170(4):866–73. https://doi.org/10.1111/bjd.12783.CrossRefPubMed

47.

Ortonne N, Valeyrie-Allanore L, Bastuji-Garin S, Wechsler J, de Feraudy S, Duong TA, et al. Histopathology of drug rash with eosinophilia and systemic symptoms syndrome: a morphological and phenotypical study. Br J Dermatol. 2015;173(1):50–8. https://doi.org/10.1111/bjd.13683.CrossRefPubMed

48.

Skowron F, Bensaid B, Balme B, Depaepe L, Kanitakis J, Nosbaum A, et al. Comparative histological analysis of drug-induced maculopapular exanthema and DRESS. J Eur Acad Dermatol Venereol. 2016;30(12):2085–90. https://doi.org/10.1111/jdv.13832.CrossRefPubMed

49.

Jeong J, Sim DW, Yu JE, Choi YD, Kim SK, Yoon W, et al. Differentiation of angioimmunoblastic T-cell lymphoma from DRESS syndrome. J Allergy Clin Immunol Pract. 2019;7(5):1684–6 e1. https://doi.org/10.1016/j.jaip.2018.11.048.

50.

Cardones AR. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. Clin Dermatol. 2020;38(6):702–11. https://doi.org/10.1016/j.clindermatol.2020.06.008.CrossRefPubMed

51.

Kim DH, Koh YI. Comparison of diagnostic criteria and determination of prognostic factors for drug reaction with eosinophilia and systemic symptoms syndrome. Allergy Asthma Immunol Res. 2014;6(3):216–21. https://doi.org/10.4168/aair.2014.6.3.216.CrossRefPubMedPubMedCentral

52.

Isaacs M, Cardones AR, Rahnama-Moghadam S. DRESS syndrome: clinical myths and pearls. Cutis. 2018;102(5):322–6.PubMed

53.

Bouvresse S, Valeyrie-Allanore L, Ortonne N, Konstantinou MP, Kardaun SH, Bagot M, et al. Toxic epidermal necrolysis, DRESS, AGEP: do overlap cases exist? Orphanet J Rare Dis. 2012;7:72. https://doi.org/10.1186/1750-1172-7-72.CrossRefPubMedPubMedCentral

54.

Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: Part II. Management and therapeutics. J Am Acad Dermatol. 2013;68(5):709 e1–9; quiz 18–20. https://doi.org/10.1016/j.jaad.2013.01.032.

55.

Suthumchai N, Srinoulprasert Y, Thantiworasit P, Rerknimitr P, Tuchinda P, Chularojanamontri L, et al. The measurement of drug-induced interferon gamma-releasing cells and lymphocyte proliferation in severe cutaneous adverse reactions. J Eur Acad Dermatol Venereol. 2018;32(6):992–8. https://doi.org/10.1111/jdv.14890.CrossRefPubMed

56.

Trubiano JA, Strautins K, Redwood AJ, Pavlos R, Konvinse KC, Aung AK, et al. The combined utility of ex vivo IFN-gamma release enzyme-linked immunospot assay and in vivo skin testing in patients with antibiotic-associated severe cutaneous adverse reactions. J Allergy Clin Immunol Pract. 2018;6(4):1287–96 e1. https://doi.org/10.1016/j.jaip.2017.09.004.

57.•

Cabanas R, Calderon O, Ramirez E, Fiandor A, Caballero T, Heredia R, et al. Sensitivity and specificity of the lymphocyte transformation test in drug reaction with eosinophilia and systemic symptoms causality assessment. Clin Exp Allergy. 2018;48(3):325–333. https://doi.org/10.1111/cea.13076. Assesses and optimizes the sensitivity and specificity of the LTT to specific drugs in DRESS patients to allow for clinical implementation. LTT was particularly useful when testing anticonvulsants, antituberculosis medications, and beta-lactams.

58.

Santiago F, Goncalo M, Vieira R, Coelho S, Figueiredo A. Epicutaneous patch testing in drug hypersensitivity syndrome (DRESS). Contact Dermatitis. 2010;62(1):47–53. https://doi.org/10.1111/j.1600-0536.2009.01659.x.CrossRefPubMed

59.

Barbaud A, Collet E, Milpied B, Assier H, Staumont D, Avenel-Audran M, et al. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions. Br J Dermatol. 2013;168(3):555–62. https://doi.org/10.1111/bjd.12125.CrossRefPubMed

60.

Lehloenya RJ, Isaacs T, Nyika T, Dhana A, Knight L, Veenstra S, et al. Early high-dose intravenous corticosteroids rapidly arrest Stevens Johnson syndrome and drug reaction with eosinophilia and systemic symptoms recurrence on drug re-exposure. J Allergy Clin Immunol Pract. 2021;9(1):582–4 e1. https://doi.org/10.1016/j.jaip.2020.08.012.

61.

Shiohara T, Kano Y. Drug reaction with eosinophilia and systemic symptoms (DRESS): incidence, pathogenesis and management. Expert Opin Drug Saf. 2017;16(2):139–47. https://doi.org/10.1080/14740338.2017.1270940.CrossRefPubMed

62.

Natkunarajah J, Goolamali S, Craythorne E, Benton E, Smith C, Morris-Jones R, et al. Ten cases of drug reaction with eosinophilia and systemic symptoms (DRESS) treated with pulsed intravenous methylprednisolone. Eur J Dermatol. 2011;21(3):385–91. https://doi.org/10.1684/ejd.2011.1300.CrossRefPubMed

63.

Funck-Brentano E, Duong TA, Bouvresse S, Bagot M, Wolkenstein P, Roujeau JC, et al. Therapeutic management of DRESS: a retrospective study of 38 cases. J Am Acad Dermatol. 2015;72(2):246–52. https://doi.org/10.1016/j.jaad.2014.10.032.CrossRefPubMed

64.

Morikawa D, Hiraoka E, Obunai K, Norisue Y. Myocarditis associated with drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a case report and review of the literature. Am J Case Rep. 2018;19:978–84. https://doi.org/10.12659/AJCR.909569.CrossRefPubMedPubMedCentral

65.•

Tohyama M, Hashimoto K, Oda F, Namba C, Sayama K. Influence of corticosteroid therapy on viral reactivation in drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. J Dermatol. 2020;47(5):476–482. https://doi.org/10.1111/1346-8138.15294. Study showing that high-dose corticosteroid treatment initiated within 1 week after disease onset interfered with HHV‐6 reactivation with remarkable suppression of serum sIL‐2R levels.

66.

Nguyen E, Yanes D, Imadojemu S, Kroshinsky D. Evaluation of cyclosporine for the treatment of DRESS syndrome. JAMA Dermatol. 2020;156(6):704–6. https://doi.org/10.1001/jamadermatol.2020.0048.CrossRefPubMedPubMedCentral

67.

Joly P, Janela B, Tetart F, Rogez S, Picard D, D’Incan M, et al. Poor benefit/risk balance of intravenous immunoglobulins in DRESS. Arch Dermatol. 2012;148(4):543–4. https://doi.org/10.1001/archderm.148.4.dlt120002-c.CrossRefPubMed

68.

Damsky WE, Vesely MD, Lee AI, Choi J, Meyer AC, Chen M, et al. Drug-induced hypersensitivity syndrome with myocardial involvement treated with tofacitinib. JAAD Case Rep. 2019;5(12):1018–26. https://doi.org/10.1016/j.jdcr.2019.07.004.CrossRefPubMedPubMedCentral

69.

Chen YC, Chang CY, Cho YT, Chiu HC, Chu CY. Long-term sequelae of drug reaction with eosinophilia and systemic symptoms: a retrospective cohort study from Taiwan. J Am Acad Dermatol. 2013;68(3):459–65. https://doi.org/10.1016/j.jaad.2012.08.009.CrossRefPubMed

70.

Kano Y, Tohyama M, Aihara M, Matsukura S, Watanabe H, Sueki H, et al. Sequelae in 145 patients with drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms: survey conducted by the Asian Research Committee on Severe Cutaneous Adverse Reactions (ASCAR). J Dermatol. 2015;42(3):276–82. https://doi.org/10.1111/1346-8138.12770.CrossRefPubMed

71.

Lew TT, Creamer D, Mackenzie J, Walsh SA. Post-traumatic stress disorder following drug reaction with eosinophilia and systemic symptoms. Br J Dermatol. 2015;172(3):836–7. https://doi.org/10.1111/bjd.13375.CrossRefPubMed

72.

Mounzer K, Hsu R, Fusco JS, Brunet L, Henegar CE, Vannappagari V, et al. HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA((R)) observational database: a cohort study. AIDS Res Ther. 2019;16(1):1. https://doi.org/10.1186/s12981-019-0217-3.CrossRefPubMedPubMedCentral

73.

Quiros-Roldan E, Gardini G, Properzi M, Ferraresi A, Carella G, Marchi A, et al. Abacavir adverse reactions related with HLA-B*57: 01 haplotype in a large cohort of patients infected with HIV. Pharmacogenet Genomics. 2020;30(8):167–74. https://doi.org/10.1097/FPC.0000000000000409.CrossRefPubMed

74.

Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 2005;102(11):4134–9. https://doi.org/10.1073/pnas.0409500102.CrossRefPubMedPubMedCentral

75.

Kang HR, Jee YK, Kim YS, Lee CH, Jung JW, Kim SH, et al. Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genomics. 2011;21(5):303–7. https://doi.org/10.1097/FPC.0b013e32834282b8.CrossRefPubMed

76.

Sukasem C, Jantararoungtong T, Kuntawong P, Puangpetch A, Koomdee N, Satapornpong P, et al. HLA-B (*) 58:01 for allopurinol-induced cutaneous adverse drug reactions: implication for clinical interpretation in Thailand. Front Pharmacol. 2016;7:186. https://doi.org/10.3389/fphar.2016.00186.CrossRefPubMedPubMedCentral

77.

Genin E, Chen DP, Hung SI, Sekula P, Schumacher M, Chang PY, et al. HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis. Pharmacogenomics J. 2014;14(3):281–8. https://doi.org/10.1038/tpj.2013.40.CrossRefPubMed

78.

McCormack M, Alfirevic A, Bourgeois S, Farrell JJ, Kasperaviciute D, Carrington M, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med. 2011;364(12):1134–43. https://doi.org/10.1056/NEJMoa1013297.CrossRefPubMedPubMedCentral

79.

Niihara H, Kakamu T, Fujita Y, Kaneko S, Morita E. HLA-A31 strongly associates with carbamazepine-induced adverse drug reactions but not with carbamazepine-induced lymphocyte proliferation in a Japanese population. J Dermatol. 2012;39(7):594–601. https://doi.org/10.1111/j.1346-8138.2011.01457.x.CrossRefPubMed

80.

Ozeki T, Mushiroda T, Yowang A, Takahashi A, Kubo M, Shirakata Y, et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet. 2011;20(5):1034–41. https://doi.org/10.1093/hmg/ddq537.CrossRefPubMed

81.

Zhang FR, Liu H, Irwanto A, Fu XA, Li Y, Yu GQ, et al. HLA-B*13:01 and the dapsone hypersensitivity syndrome. N Engl J Med. 2013;369(17):1620–8. https://doi.org/10.1056/NEJMoa1213096.CrossRefPubMed

82.

Tempark T, Satapornpong P, Rerknimitr P, Nakkam N, Saksit N, Wattanakrai P, et al. Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with HLA-B*13: 01 allele in the Thai population. Pharmacogenet Genomics. 2017;27(12):429–37. https://doi.org/10.1097/FPC.0000000000000306.CrossRefPubMed

83.

Chen WT, Wang CW, Lu CW, Chen CB, Lee HE, Hung SI, et al. The function of HLA-B*13:01 involved in the pathomechanism of dapsone-induced severe cutaneous adverse reactions. J Invest Dermatol. 2018;138(7):1546–54. https://doi.org/10.1016/j.jid.2018.02.004.CrossRefPubMed

84.

Satapornpong P, Pratoomwun J, Rerknimitr P, Klaewsongkram J, Nakkam N, Rungrotmongkol T, et al. HLA-B*13:01 is a predictive marker of dapsone-induced severe cutaneous adverse reactions in Thai patients. Front Immunol. 2021;12: 661135. https://doi.org/10.3389/fimmu.2021.661135.CrossRefPubMedPubMedCentral

85.

Manuyakorn W, Likkasittipan P, Wattanapokayakit S, Suvichapanich S, Inunchot W, Wichukchinda N, et al. Association of HLA genotypes with phenytoin induced severe cutaneous adverse drug reactions in Thai children. Epilepsy Res. 2020;162: 106321. https://doi.org/10.1016/j.eplepsyres.2020.106321.CrossRefPubMed

86.

Thomas M, Hopkins C, Duffy E, Lee D, Loulergue P, Ripamonti D, et al. Association of the HLA-B*53:01 allele with drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome during treatment of HIV infection with raltegravir. Clin Infect Dis. 2017;64(9):1198–203. https://doi.org/10.1093/cid/cix096.CrossRefPubMedPubMedCentral

87.

Konvinse KC, Trubiano JA, Pavlos R, James I, Shaffer CM, Bejan CA, et al. HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms. J Allergy Clin Immunol. 2019;144(1):183–92. https://doi.org/10.1016/j.jaci.2019.01.045.CrossRefPubMedPubMedCentral

88.

Cacoub P, Musette P, Descamps V, Meyer O, Speirs C, Finzi L, et al. The DRESS syndrome: a literature review. Am J Med. 2011;124(7):588–97. https://doi.org/10.1016/j.amjmed.2011.01.017.CrossRefPubMed

89.

Cho YT, Yang CW, Chu CY. Drug reaction with eosinophilia and systemic symptoms (DRESS): an interplay among drugs, viruses, and immune system. Int J Mol Sci. 2017;18(6). https://doi.org/10.3390/ijms18061243.

90.

Di Palma-Grisi JC, Vijayagopal K, Muslimani MA. Case reports of DRESS syndrome and symptoms consistent with DRESS syndrome following treatment with recently marketed monoclonal antibodies. Autoimmune Dis. 2019;2019:7595706. https://doi.org/10.1155/2019/7595706.CrossRefPubMedPubMedCentral

Titel: Updates and Insights in the Diagnosis and Management of DRESS Syndrome
verfasst von: Elisa Maria Schunkert
Sherrie Jill Divito
Publikationsdatum: 09.11.2021
Verlag: Springer US
Erschienen in: Current Dermatology Reports / Ausgabe 4/2021
Elektronische ISSN: 2162-4933
DOI: https://doi.org/10.1007/s13671-021-00348-z

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2021

Social Media and Ethical Challenges for the Dermatologist

Contact Dermatitis to Nail Cosmetics

Occupational Contact Dermatitis: An Individualized Approach to the Worker with Dermatitis

Social Media in Dermatology and an Overview of Popular Social Media Platforms

Recognition and Management of Toxic Erythema of Chemotherapy for the Inpatient Dermatologist